FranÃ§ois Mach

List of Publications by Year
in descending order

169 papers	26,653 citations

66343

42 h-index	

7160

153 g-index	

172 all docs	172 docs citations

172 times ranked	32657 citing authors

#	Article	IF	Citations
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
2	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
3	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
4	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
5	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
6	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	27.8	1,328
7	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	2.2	1,024
8	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
9	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal, 2016, 37, 1967-1976.	2.2	433
10	Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 2005, 434, 782-786.	27.8	403
11	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 633-643.	27.0	366
12	The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nature Genetics, 2016, 48, 1171-1184.	21.4	362
13	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. European Heart Journal, 2017, 38, ehw582.	2.2	317
14	Adverse effects of statin therapy: perception vs. the evidence â€" focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	2.2	262
15	Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 373-379.	2.4	254
16	2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology, 2020, 25, 3826.	1.4	199
17	CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. Journal of Molecular and Cellular Cardiology, 2009, 46, 612-620.	1.9	153
18	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. European Heart Journal, 2018, 39, 1172-1180.	2.2	150

#	Article	IF	Citations
19	Evolocumab for Early Reduction of LDLÂCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 2019, 74, 2452-2462.	2.8	135
20	Lipoprotein(a): the revenant. European Heart Journal, 2017, 38, 1553-1560.	2.2	133
21	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 2015, 36, 2438-2445.	2.2	129
22	CB$_2$ cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1145-H1155.	3.2	127
23	Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. European Heart Journal, 2011, 32, 1369-1378.	2.2	123
24	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal, 2016, 37, 546-553.	2.2	120
25	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. European Heart Journal, 2011, 32, 412-421.	2.2	110
26	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 1317-1327.	27.0	108
27	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. Stroke, 2010, 41, 1394-1404.	2.0	106
28	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	102	
29	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. Circulation, 2016, 134, 698-709.	1.6	99
30	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal, 2022, 43, 830-833.	2.2	92
31	Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis. Mediators of Inflammation, 2014, 2014, 1-9.	3.0	82
32	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. European Heart Journal, 2012, 33, 846-856.	2.2	81
33	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. European Heart Journal, 2019, 40, 2700-2709.	2.2	79
34	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 129-138.	1.0	70
35	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis, 2009, 205, 433-441.	0.8	67
36	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63

#	Article	IF	Citations
37	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	2.8	62
38	Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxidants and Redox Signaling, 2015, 23, 460-489.	5.4	56
39	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	6.1	56
40	Sphingosine-1-phosphate reduces ischaemiaâ€"reperfusion injury by phosphorylating the gap junction protein Connexin43. Cardiovascular Research, 2016, 109, 385-396.	3.8	55
41	Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, doubleâ€blind, placeboâ€controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâ€lowering therapyâ€"A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial. Clinical Cardiology, 2017, 40, 59-65.	1.8	54
42	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. European Heart Journal, 2017, 38, 3493-3502.	2.2	46
43	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. Cardiovascular Research, 2022, 118, 2367-2384.	3.8	45
44	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. Cardiovascular Research, 2018, 114, 1178-1188.	3.8	44
45	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. European Heart Journal, 2018, 39, 4109-4111.	2.2	44
46	Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. Vascular Pharmacology, 2015, 64, 16-27.	2.1	42
47	Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury. Journal of Molecular and Cellular Cardiology, 2016, 94, 82-94.	1.9	41
48	Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury. PLoS ONE, 2015, 10, e0119664.	2.5	40
49	Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. European Journal of Clinical Investigation, 2015, 45, 579-586.	3.4	40
50	Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. International Journal of Cardiology, 2018, 255, 195-199.	1.7	40
51	NLRP3 Inflammasome Activation Controls Vascular Smooth Muscle Cells Phenotypic Switch in Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 340.	4.1	40
52	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart, 2015, 101, 854-863.	2.9	38
53	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. European Journal of Internal Medicine, 2015, 26, 56-62.	2.2	37
54	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. European Heart Journal, 2015, 36, 516-526.	2.2	37

#	Article	IF	Citations
55	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.8	37
56	Update on the Role of Cannabinoid Receptors after Ischemic Stroke. Mediators of Inflammation, 2012, 2012, 1-8.	3.0	34
57	Stairs instead of elevators at the workplace decreases <scp>PCSK</scp>9 levels in a healthy population. European Journal of Clinical Investigation, 2015, 45, 1017-1024.	3.4	34
58	Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 770.	1.6	34
59	Recombinant Tissue Plasminogen Activator Enhances Microglial Cell Recruitment after Stroke in Mice. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 802-812.	4.3	31
60	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. European Heart Journal, 2016, 37, 3569-3575.	2.2	30
61	Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms. Frontiers in Immunology, 2017, 8, 437.	4.8	30
62	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
63	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	29
64	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
65	Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. European Heart Journal, 2022, 43, 1849-1860.	2.2	28
66	Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2342-2349.	2.4	27
67	Lipid management in ACS: Should we go lower faster?. Atherosclerosis, 2018, 275, 368-375.	0.8	27
68	Impact of the COVID-19 pandemic on acute coronary syndromes. Swiss Medical Weekly, 2020, 150, w20448.	1.6	27
69	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-<i>Î°</i>B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	26
70	The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?. PLoS ONE, 2015, 10, e0132780.	2.5	26
71	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.8	26
72	Cardiovascular risk and testosterone â€" from subclinical atherosclerosis to lipoprotein function to heart failure. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 257-274.	5.7	26

#	Article	IF	Citations
73	Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration. International Journal of Cardiology, 2018, 272, 13-19.	1.7	25
74	European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2022, 29, 1060-1071.	1.8	25
75	Apelinâ€13 treatment enhances the stability of atherosclerotic plaques. European Journal of Clinical Investigation, 2018, 48, e12891.	3.4	24
76	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2019, 49, e13117.	3.4	24
77	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atherosclerosis Supplements, 2020, 42, e49-e58.	1.2	23
78	Inflammation during acute coronary syndromes â€" Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	1.7	22
79	Toward a Role for Statins in Immunomodulation. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 478-480.	3.4	22
80	Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis. Vascular Pharmacology, 2018, 102, 37-43.	2.1	21
81	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE, 2018, 13, e0195174.	2.5	21
82	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs, 2020, 80, 229-239.	10.9	21
83	An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	20
84	The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thrombosis and Haemostasis, 2013, 110, 940-958.	3.4	20
85	Leptin/adiponectin ratio predicts poststroke neurological outcome. European Journal of Clinical Investigation, 2015, 45, 1184-1191.	3.4	20
86	Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice. Vascular Pharmacology, 2015, 74, 103-113.	2.1	20
87	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. Vascular Pharmacology, 2016, 85, 57-65.	2.1	20
88	Design of the randomized, placeboâ€controlled evolocumab for early reduction of LDLâ€cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clinical Cardiology, 2018, 41, 1513-1520.	1.8	20
89	Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. International Journal of Cardiology, 2018, 263, 138-141.	1.7	20
90	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre beforeâ€"after study with parallel group comparisons. BMJ Open, 2016, 6, e011520.	1.9	18

#	Article	IF	Citations
91	The quest for endothelial atypical cannabinoid receptor: BKCa channels act as cellular sensors for cannabinoids in in vitro and in situ endothelial cells. Vascular Pharmacology, 2018, 102, 44-55.	2.1	18
92	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. Mediators of Inflammation, 2016, 2016, 1-10.	3.0	17
93	Antiâ€ApoAâ€1 IgG serum levels predict worse poststroke outcomes. European Journal of Clinical Investigation, 2016, 46, 805-817.	3.4	17
94	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging studyâ€"Rationale and design of the PACMAN-AMI trial. American Heart Journal, 2021, 238, 33-44.	2.7	17
95	Alamandine abrogates neutrophil degranulation in atherosclerotic mice. European Journal of Clinical Investigation, 2017, 47, 117-128.	3.4	15
96	Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease. International Journal of Molecular Sciences, 2018, 19, 295.	4.1	15
97	Prognostic value of pulse pressure after an acute coronary syndrome. Atherosclerosis, 2018, 277, 219-226.	0.8	15
98	Follicular regulatory T cell in atherosclerosis. Journal of Leukocyte Biology, 2018, 104, 925-930.	3.3	15
99	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascular Pharmacology, 2015, 72, 197-208.	2.1	14
100	Health utility indexes in patients with acute coronary syndromes. Open Heart, 2016, 3, e000419.	2.3	14
101	The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study. Journal of Health Psychology, 2017, 22, 208-217.	2.3	14
102	GPR55 agonist lysophosphatidylinositol and lysophosphatidylcholine inhibit endothelial cell hyperpolarization via GPR-independent suppression of Na+-Ca2+ exchanger and endoplasmic reticulum Ca2+ refilling. Vascular Pharmacology, 2017, 89, 39-48.	2.1	14
103	Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation. Journal of International Medical Research, 2018, 46, 5183-5194.	1.0	14
104	Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode. Swiss Medical Weekly, 2021, 151, w30093.	1.6	14
105	PCSK9 inhibitors. Swiss Medical Weekly, 2015, 145, w14094.	1.6	13
106	Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay. PLoS ONE, 2016, 11, e0161493.	2.5	13
107	Direct activation of Ca2+ and voltage-gated potassium channels of large conductance by anandamide in endothelial cells does not support the presence of endothelial atypical cannabinoid receptor. European Journal of Pharmacology, 2017, 805, 14-24.	3.5	13
108	Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis. European Journal of Clinical Investigation, 2018, 48, e12888.	3.4	13

#	Article	IF	Citations
109	Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. Journal of Clinical Medicine, 2019, 8, 1225.	2.4	13
110	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. Thrombosis and Haemostasis, 2020, 120, 168-180.	3.4	13
111	Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet. Cardiovascular Research, 2021, 117, 743-755.	3.8	13
112	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. Journal of Infection, 2018, 76, 186-195.	3.3	12
113	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	11
114	Lipoprotein(a): the perpetual supporting actor. European Heart Journal, 2018, 39, 2597-2599.	2.2	11
115	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. Journal of Clinical Medicine, 2019, 8, 1002.	2.4	11
116	Single-Cell RNA-Seq Reveals a Crosstalk between Hyaluronan Receptor LYVE-1-Expressing Macrophages and Vascular Smooth Muscle Cells. Cells, 2022, 11, 411.	4.1	11
117	Single-Cell Analysis Uncovers Osteoblast Factor Growth Differentiation Factor 10 as Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation Associated with Plaque Rupture in Human Carotid Artery Disease. International Journal of Molecular Sciences, 2022, 23, 1796.	4.1	11
118	Inflammation Is a Key Pathophysiological Feature of Metabolic Syndrome. Mediators of Inflammation, 2013, 2013, 1-2.	3.0	10
119	Sweet<i>less</i>'n low LDL-C targets for PCSK9 treatment : FigureÂ1. European Heart Journal, 2015, 36, 1146-1148.	2.2	10
120	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	2.4	10
121	Towards a therapeutic use of selective CB2cannabinoid receptor ligands for atherosclerosis. Future Cardiology, 2006, 2, 49-53.	1.2	9
122	Implementation strategies of Systems Medicine in clinical research and home care for cardiovascular disease patients. European Journal of Internal Medicine, 2014, 25, 785-794.	2.2	9
123	Decreased serum <scp>PCSK</scp>9 levels after ischaemic stroke predict worse outcomes. European Journal of Clinical Investigation, 2016, 46, 1053-1062.	3.4	9
124	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. Cardiology Research and Practice, 2018, 2018, 1-11.	1.1	9
125	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naÃ¯ve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis, 2019, 284, 253-259.	0.8	9
126	Cardiotrophin-1 Deficiency Abrogates Atherosclerosis Progression. Scientific Reports, 2020, 10, 5791.	3.3	9

#	Article	IF	Citations
127	Air pollution triggers inflammation and cardiovascular events: now is the time to act. European Heart Journal, 2021, 42, 773-775.	2.2	9
128	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	1.0	9
129	Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation. Journal of Molecular and Cellular Cardiology, 2018, 115, 54-63.	1.9	8
130	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2020, 13, 618-628.	2.4	8
131	Atherosclerotic plaque vulnerability is increased in mouse model of lupus. Scientific Reports, 2020, 10, 18324.	3.3	8
132	Anti-Apolipoprotein A-1 IgG Influences Neutrophil Extracellular Trap Content at Distinct Regions of Human Carotid Plaques. International Journal of Molecular Sciences, 2020, 21, 7721.	4.1	8
133	Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence. Journal of Cardiovascular Medicine, 2020, 21, 80-82.	1.5	8
134	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology, 2022, 28, 2030-2037.	1.8	8
135	A Short Intervention Followed by an Interactive E-Learning Module to Motivate Medical Students to Enlist as First Responders: Protocol for a Prospective Implementation Study. JMIR Research Protocols, 2020, 9, e24664.	1.0	8
136	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Advances in Therapy, 2022, 39, 504-517.	2.9	8
137	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. American Heart Journal, 2022, 247, 33-41.	2.7	8
138	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. Vascular Pharmacology, 2015, 71, 84-92.	2.1	7
139	Impact of long distance rowing on biological health: A pilot study. Clinical Biochemistry, 2018, 52, 142-147.	1.9	7
140	Serum cardiovascular risk biomarkers in preâ€‘pubertal obese children. European Journal of Clinical Investigation, 2018, 48, e12995.	3.4	7
141	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 589-598.	1.0	7
142	Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242.	1.8	7
143	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS ONE, 2019, 14, e0211464.	2.5	6
144	Optimal Timing of Invasive Coronary Angiography following NSTEMI. Journal of Interventional Cardiology, 2020, 2020, 1-9.	1.2	6

#	Article	IF	Citations
145	A Short Intervention and an Interactive e-Learning Module to Motivate Medical and Dental Students to Enlist as First Responders: Implementation Study. Journal of Medical Internet Research, 2022, 24, e38508.	4.3	6
146	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2019, 8, 1684.	2.4	5
147	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. International Journal of Cardiology, 2020, 303, 8-13.	1.7	5
148	So lowâ€¦ so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. European Heart Journal, 2018, 39, 382-384.	2.2	4
149	The â€˜ten commandmentsâ€™ for the 2021 ESC Guidelines on CVD prevention. European Heart Journal, 2022, 43, 174-176.	2.2	4
150	Cysteineâ€Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq0 0 0 rgBT /Overlock 1 Heart Association, 2021, 10, e020488.	3.7	4
151	New anti-inflammatory agents to reduce atherosclerosis. Archives of Physiology and Biochemistry, 2006, 112, 130-137.	2.1	3
152	Reduced adrenal stress response in patients on PCSK9 inhibitor therapy. Atherosclerosis, 2021, 325, 63-68.	0.8	3
153	PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. Current Medicinal Chemistry, 2022, 29, 1016-1026.	2.4	3
154	Use and role of monoclonal antibodies and other biologics in preventive cardiology. Swiss Medical Weekly, 2015, 145, w14179.	1.6	3
155	Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about Sex. Thrombosis and Haemostasis, 2019, 119, 1379-1381.	3.4	2
156	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2016, 146, w14275.	1.6	2
157	Determinants of hospital length of stay after transcatheter aortic valve implantation with self-expanding prostheses: a prospective, single centre observational study. Swiss Medical Weekly, 2019, 149, w20095.	1.6	2
158	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	2.6	2
159	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	2.2	1
160	4D cardiac imaging at clinical 3.0 T provides accurate assessment of murine myocardial function and viability. Magnetic Resonance Imaging, 2017, 44, 46-54.	1.8	1
161	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	1.7	1
162	Prognosis of Laboratory-Confirmed Influenza and Respiratory Syncytial Virus in Acute Heart Failure. Journal of Clinical Medicine, 2021, 10, 4546.	2.4	1

#	Article	IF	Citations
163	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	1.6	1
164	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. Swiss Medical Weekly, 2019, 149, w20049.	1.6	1
165	Intravascular lithotripsy to treat an ostial left main coronary artery stenosis due to porcelain aorta in a patient with congenital HDL deficiency. Anatolian Journal of Cardiology, 2020, 24, 345-346.	0.9	1
166	A9.11â€¦Anti-apolipoprotein A1 autoantibodies induce tissue factor activity and expression: a role in atherothrombosis. Annals of the Rheumatic Diseases, 2014, 73, A96.1-A96.	0.9	0
167	Myeloid IL-10 receptor signalling as pro-atherogenic factor modulating cholesterol homeostasis. Thrombosis and Haemostasis, 2016, 116, 407-407.	3.4	0
168	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Preventive Medicine Reports, 2021, 24, 101583.	1.8	0
169	New concepts in the management of dyslipidaemiaa. Swiss Medical Weekly, 2016, 146, w14378.	1.6	0